June 1, 2013New England Journal of Medicine3,424 citationsOpen Access
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement. (Funded by Pfizer; ClinicalTrials.gov number, NCT00932893.).
Cite This Study
Shaw et al. (2013) studied this question.